KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Hims & Hers Health (HIMS) EBITDA (2019 - 2025)

Hims & Hers Health (HIMS) has disclosed EBITDA for 7 consecutive years, with $22.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 13.73% to $22.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.0 million through Dec 2025, up 4.09% year-over-year, with the annual reading at $131.0 million for FY2025, 4.09% up from the prior year.
  • EBITDA hit $22.0 million in Q4 2025 for Hims & Hers Health, up from $15.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $76.0 million in Q3 2024 to a low of -$51.5 million in Q1 2021.
  • Historically, EBITDA has averaged $3.0 million across 5 years, with a median of -$7.4 million in 2023.
  • Biggest five-year swings in EBITDA: tumbled 853.08% in 2021 and later soared 1931.26% in 2024.
  • Year by year, EBITDA stood at -$31.2 million in 2021, then soared by 65.69% to -$10.7 million in 2022, then soared by 111.7% to $1.3 million in 2023, then skyrocketed by 1931.26% to $25.5 million in 2024, then dropped by 13.73% to $22.0 million in 2025.
  • Business Quant data shows EBITDA for HIMS at $22.0 million in Q4 2025, $15.9 million in Q3 2025, and $43.5 million in Q2 2025.